We observed that tasquinimod lowered the TGFβ, PI3K, and p53 pathway activity in JAK2V617F disease, all known players in MPN and MF, specifically in CD41+ megakaryocytes and CD11b+Gr1− monocytes (Figure 1C). Here, TGFB1 is linked to myeloproliferative disorder.